

ROUAS-FREISS Nathalie

Birth date: 5 October 1963

Citizenship: French

Current position: Research Director CEA, Head of Hemato-Immunology Research Department, CEA-DRF-IBFJ-SRHI, Team 13 Leader - INSERM U1342, IRSL, Saint-Louis Hospital, 1 avenue C. Vellefaux 75010

Paris, France

Tel. 33 1 57 27 68 01 – Fax. 33 1 48 03 19 60. E-mail: Nathalie.Rouas-Freiss@cea.fr

University degrees and qualifications

1992	Pharm.D – University Paris V, France
1993	Ph.D. in Immunology – University Paris VII, France
2002	« Habilitation à Diriger des Recherches », University Paris XI, France
2011	Senior Expert CEA
2019	Research Director Expert, CEA
2022	Expert Fellow, CEA

Awards

1987	<i>Lauréat</i> of the Faculty of Pharmacy – University Paris V, France
2002	Dagnan-Bouveret Prize from the Academy of Sciences – France Institute

Scientific Career

1989-1993	Master and Ph.D. of Science in Immunology, University Paris VII, France
1993-1995	Post-doctoral Research Fellow, INSERM U255, Dr Fridman, Curie Institute, Paris, France and INSERM U333, Pr Triebel, Gustave Roussy Institute, Villejuif, France
1995-1996	Assistant Professor of Immunology, Department of Immunology, CNRS URA 1484, Pr Bellet, University Paris V, France
1996-2002	Researcher at the Commissariat à l'Energie Atomique, Hemato-Immunology Research Department, Dr Carosella, Saint-Louis Hospital Paris, France
2002-2022	Head of Laboratory at the Commissariat à l'Energie Atomique
2019-2024	Team Leader, INSERM U 976, IRSL, Saint-louis Hospital, Paris, France
Since 2022	Head of Hemato-Immunology Research Department, CEA-DRF-IBFJ-SRHI
Since 2025	Team 13 Leader, INSERM U 1342, IRSL, Saint-louis Hospital, Paris, France

Grants

7th European Program (2010-2015)
 National Agency of Research ANR (2011-2014) (2015-2021) (2025-2028)
 Cancer Foundation ARC (1997, 1998, 2002, 2004)
 Vaincre la Mucoviscidose (1999, 2000, 2001, 2007, 2008, 2012, 2016, 2018, 2020, 2025)
 Agence de la Biomédecine (1997, 2000, 2002, 2003, 2008, 2014, 2018)
 Fondation pour la Recherche Médicale (2012, 2023-2026)
 Legs Poix (2014)
 China scholarship council (2014)
 CEA-CFR PhD Student (2001, 2005, 2008, 2009, 2017, 2021)
 Cancéropole (2008, 2018)
 INCA (2019-2023)
 Fondation Air Liquide (2020-2023)
 European Grant Resilience (2026-2028)
 PEPR Biotherapie (2025-2029)

Supervision of graduate students and postdoctoral fellows

PhD and post-docs: 14
 Master students: 16
 Technician students: 15

Teaching Activities

- DU thérapie cellulaire, Institut d'Hématologie, Hôpital Saint-Louis, Université Paris 7
 - MSBM, Université Denis Diderot, Paris 7

- DEA Physiologie du développement, Université Denis Diderot, Paris 7
- DESC Cancérologie, Institut Gustave Roussy, Villejuif.
- M2 Relations Hôte-Greffon, Université Paris Saclay
- M2 Biochimie, cellules, Cibles thérapeutiques, Université Paris Diderot, Paris 7
- M2 de Physiologie du placenta, Université Paris Cité
- Immunology training, University of Sao-Paulo, Ribeiro-Preto, Brazil

Scientific Expertise and Committee Membership

- Member of the French Society of Immunology
- Reviewer for international scientific journals: Blood, Journal of Cellular and Molecular Medicine, Journal of Hepatology, American Journal of Transplantation, Human Immunology, Tissue Antigens, Immunology, Haematologica, Human Reproduction, Obstetrics and Gynecology, Cancer Investigation, Annals of Surgical Oncology, Clinical Oncology, Lupus, American Journal of Respiratory and Critical Care Medicine, Molecular Medicine, Leukemia, Oncotarget, OncoImmunology, European Journal of Immunology, Stem Cell Development, Plos One
- Editor for Transplantation Proceedings (Vol. 31, N°4, June 1999); Seminars in Cancer Biology (Vol. 9, N°1, February 1999) - (Vol. 13, N°5, October 2003) - (Vol. 17, N°6, 2007); Human Immunology for HLA-G Conference; Journal of Immunology Research (Guest Editor, HLA-Ib Issue 2017)
- Expert for the Ligue Nationale Contre le Cancer (national comitee 2013-2017), INSERM, Agence de la Biomédecine, Fund for Scientific Research (Belgium), University Paris 7, Israel Science Foundation, EFS, University PSL
- Scientific Committee of the HLA-G International Conference (1998, 2000, 2003, 2006, 2009, 2012, 2015, 2019, 2022) - Co-organizer of International Workshops on HLA-G and HLA-E (2000, 2003, 2006)

Publications: 144 (PubMed) (h-index=58, Web of Science)

Patents (2016-2026): 4

PUBLICATIONS

1. ORIGINAL ARTICLES IN INTERNATIONAL PEER REVIEWED JOURNALS

Laboureur R, Dumont C, Koca D, Lugand L, Bossis M, Artru E, Jacquier A, Verine J, Bouhidel F, Djouadou M, Masson-Lecomte A, Russick J, Carosella ED, Desgrandchamps F, Guyon L, Tonnerre P, LeMaoult J*, **Rouas-Freiss N***.

ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma.

Cancer Immunol Res. 2026 Jun 8. doi: 10.1158/2326-6066.

Henderson D, Knoedler L, Mathieu O, **Rouas-Freiss N**, Cetrulo CL, Lemaitre G, Smadja DM, Fortunel NO and Lellouch AG.

Porcine xenotransplantation in the clinical era: converging advances and unresolved barriers on the path to clinical translation - a narrative review

Front. Immunol. 2026 in press

Rollin P, Pluskwa B, Artru E, Le Vaslot T, Kartasheva-Ebertz D, Biron D, Bossis M, Onodi F, LeMaoult J, **Rouas-Freiss N**, Chevalier MF, Lindestam Arlehamn CS, Sette A, Masson-Lecomte A, Desgrandchamps F, Xylinas E, Tonnerre P.

BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses.

iScience. 2026 Jan 12;29(2):114676.

Brugière O, Dreyfuss D, Rong S, LeMaoult J, **Rouas-Freiss N**.

Comment on "Immunomodulatory soluble HLA-G and HLA-E are associated with rapidly deteriorating CLAD and HCMV viremia after lung transplantation".

J Heart Lung Transplant. 2025 Feb 7:S1053-2498(25)00015-4. doi: 10.1016/j.healun.2025.01.005.

Brugière O, Dreyfuss D*, Guilet R*, Rong S, Hirschi S, Renaud-Picard B, Reynaud-Gaubert M, Coiffard B, Bunel V, Messika J, Demant X, Le Pavéc J, Dauriat G, Saint Raymond C, Falque L, Mornex JF, Tissot A, Lair D, Le Borgne Krams A, Bousseau V, Magnan A, Picard C, Roux A, Glorion M, Carmagnat M, Gazeau F, Aubertin K, Carosella E, Vallée A, Landais C, **Rouas-Freiss N***, LeMaoult J*; COLT Consortium.

Circulating Vesicular-bound HLA-G as Noninvasive Predictive Biomarker of CLAD After Lung Transplantation.

Transplantation. 2025 Apr 1;109(4):736-7452024 Sep 19.

Boulanger H, Bounan S, Mahdhi A, Drouin D, Ahriz-Saksi S, Guimiot F, **Rouas-Freiss N**.

Immunologic aspects of preeclampsia.

AJOG Glob Rep. 2024 Feb 9;4(1):100321

Gallon J, LeMaoult J, Verine J, Dumont C, Djouadou M, Carosella E, **Rouas-Freiss N**, Desgrandchamps F, Masson-Lecomte A.

Profile and immune environment of upper tract urothelial carcinoma.

Prog Urol. 2023 doi: 10.1016/j.purol.

Dechavanne C., Nouatin O., Adamou R., Edslev S., Hansen A., Meurisse F., Sadissou I., Gbaguidi E., Milet J., Cottrell G., Gineau L., Sabbagh A., Massougoudji A., Moutairou K., Donadi E.A., Carosella E.D., Moreau P., Remarque E., Theisen M., **Rouas-Freiss N.**, Garcia A., Favier F.*, Courtin D.*

Placental malaria is associated with higher LILRB2 expression in monocyte subsets and lower anti-malarial IgG antibodies during infancy

Front Immunol. 2022 Jul 12;13:909831.

Lugand L.*, Mestrallet G.*, Laboureur R., Dumont C., Bouhidel F., Djouadou M., Masson-Lecomte A., Desgrandchamps F., Culine S., Carosella E.D., **Rouas-Freiss N.***, LeMaout J.*

Efficient methods for establishing a Renal Cell Carcinoma Multicellular Tumor Spheroid Model with Immune Infiltration for Immunotherapeutic Studies.

Front Oncol. 2022 Jul 28;12:898732.

Tronik-Le Roux D., Daouya M., Jacquier A., Schenowitz C., Desgrandchamps F., **Rouas-Freiss N.** and Carosella E.D.

The HLA-G immune checkpoint: a new immuno-stimulatory role for the $\alpha 1$ -domain-deleted isoform.

CMLS. 2022 May 21;79(6):310.

Brugière O., Mouren D., Trichereau J., Vallée A., Kuzniak I., Hirschi S., Renaud-Picard B., Reynaud-Gaubert M., Nieves A., Bunel V., Messika J., Demant X., Macey J., Le Pavéc J., Dauriat G., Saint-Raymond C., Falque L., Magnan A., Picard C., Roux A., Carosella E.D., Le Maout J.*, **Rouas-Freiss N.***, and the COLT Consortium

Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G.

J Heart Lung Transplant. 2022 May;41(5):626-640.

Mestrallet G., Carosella E.D., Martin M.T.*, **Rouas-Freiss N.***, Fortunel N.O.*, LeMaout J.*.

Immunosuppressive properties of epidermal keratinocytes differ according to their immaturity status

Front Immunol. 2022 Feb 11;13:786859.

Mestrallet G., Rouas-Freiss N., LeMaout J., Fortunel NO., Martin MT.

Skin Immunity and Tolerance: Focus on Epidermal Keratinocytes Expressing HLA-G.

Front Immunol. 2021 6;12:772516.

Jacquier A., Lambert T., Delattre J-F., Djouadou M., Verine J., Dumont C., Desgrandchamps F., Carosella E.D., LeMaout J.*, and **Rouas-Freiss N.***

Tumor infiltrating and peripheral CD4+ILT2+ T cells are a cytotoxic subset selectively inhibited by HLA-G in ccRCC cancer patients.

Cancer Lett. 2021 Jun 27;519:105-116.

Mestrallet G., Auvré F., Schenowitz C., Carosella E.D., LeMaout J., Martin M.T., **Rouas-Freiss N.***, and Fortunel N.O.*.

Human Keratinocytes Inhibit CD4+ T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints

Cells 2021 Jun 8;10(6):1438.

Rouas-Freiss N., Moreau P, LeMaout J, Papp B, Tronik-Le Roux D, Carosella ED.

Role of the HLA-G immune checkpoint molecule in pregnancy.

Hum Immunol. 2021 May;82(5):353-361.

Proust R, Ponsen AC, Rouffiac V, Schenowitz C, Montespan F, Ser-Le Roux K, De Leeuw F, Laplace-Builhé C, Mauduit P, Carosella ED, Banzet S, Lataillade JJ, **Rouas-Freiss N.**, Uzan G, Peltzer J.

Cord blood-endothelial colony forming cells are immunotolerated and participate at post-ischemic angiogenesis in an original dorsal chamber immunocompetent mouse model.

Stem Cell Res Ther. 2020 May 7;11(1):172.

Voisin C., Cauchois G., Reppel L., Laroye C., Louarn L., Schenowitz C., Sonon P., Poras I., Wang V., Carosella E.D., Benkirane-Jessel N., Moreau P., **Rouas-Freiss N.**, Bensoussan D., Huselstein C.

Are the immune properties of mesenchymal stem cells from Wharton Jelly maintained during chondrogenic differentiation?

J Clin Med. 2020 Feb 4;9(2).

Jacquier A., Dumont C., Carosella E.D., **Rouas-Freiss N.**, and LeMaoult J.
Cytometry-based analysis of HLA-G functions according to ILT2 expression.

Hum Immunol. 2020 Apr;81(4):168-177.

Nguyen LS, **Rouas-Freiss N**, Funck-Brentano C, Leban M, Carosella E, Touraine P, Varnous S, Bachelot A, Salem JE.

Influence of hormones on the immunotolerogenic molecule HLA-G: a cross-sectional study in patients with congenital adrenal hyperplasia.

Eur J Endocrinol. 2019 Sep 1. pii: EJE-19-0379.R3. doi: 10.1530/EJE-19-0379.

Dumont C.*, Jacquier A.*, Verine J., Noel F., Goujon A., Wu C-L., Hung T-M., Desgrandchamps F., Culine S., Carosella E.D., **Rouas-Freiss N.***, and LeMaoult J.*

CD8+PD-1-ILT2+ T cells are a major intratumor cytotoxic population selectively inhibited by the immune checkpoint HLA-G.

Cancer Immunol. Res. 2019 Oct;7(10):1619-1632. doi: 10.1158/2326-6066.

d'Almeida TC, Sadissou I, Sagbohan M, Milet J, Avokpaho E, Gineau L, Sabbagh A, Moutairou K, Donadi EA, Favier B, Penetier C, Baldet T, Moiroux N, Carosella E, Moreau P, **Rouas-Freiss N**, Cottrell G, Courtin D, Garcia A.

High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy.

Sci Rep. 2019 Jun 24;9(1):9160. doi: 10.1038/s41598-019-45688-w

Avokpaho E, d'Almeida TC, Sadissou I, Tokplonou L, Adamou R, Sonon P, Milet J, Cottrell G, Mondière A, Massougboji A, Moutairou K, Donadi EA, Teixeira Mendes Junior C, Favier B, Carosella E, Moreau P, **Rouas-Freiss N**, Garcia A, Courtin D.

HLA-G expression during hookworm infection in pregnant women.

Acta Trop. 2019 May 9;196:52-59. doi: 10.1016/j.actatropica.2019.04.026.

Naji A, Favier B, Deschaseaux F, **Rouas-Freiss N**, Eitoku M, Suganuma N.

Mesenchymal stem/stromal cell function in modulating cell death.

Stem Cell Res Ther. 2019. Feb 13;10(1):56. doi: 10.1186/s13287-019-1158-4. Review.

Naji A, Eitoku M, Favier B, Deschaseaux F, **Rouas-Freiss N**, Suganuma N.

Biological Functions of Mesenchymal Stem Cells and Clinical Implications

Cell Mol Life Sci. 2019 May 4. doi: 10.1007/s00018-019-03125-1.

Desgrandchamps F.*, LeMaoult J.*, Goujon A., Riviere A., Rivero-Juarez A., Djouadou M., de Gouvello A., Dumont C., Wu1 C-L, Culine S., Verine J., **Rouas-Freiss N.**, Hennequin C., Masson-Lecomte A., Carosella E.D.

Prediction of Non-Muscle-Invasive Bladder Cancer recurrence using checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells

Oncotarget, 2018 Sep 4;9(69):33160-33169.

Dias FC, Bertol BC, Poras I, Souto BM, Mendes-Junior CT, Castelli EC, Gineau L, Sabbagh A, **Rouas-Freiss N**, Carosella ED, Donadi EA, Moreau P.

The genetic diversity within the 1.4 kb HLA-G 5' upstream regulatory region moderately impacts on cellular microenvironment responses.

Sci Rep. 2018 Apr 4;8(1):5652. doi: 10.1038/s41598-018-24009-7

Rouas-Freiss N.*, LeMaout J.*, Verine J., Tronik-Le Roux D., Culine S., Hennequin C., Desgrandchamps F., Carosella E.D.

Intratumor Heterogeneity of Immune Checkpoints in Primary Renal Cell Cancer: Focus on HLA-G/ILT2/ILT4.

OncoImmunology, 2017 Jul 5;6(9):e1342023.

Tronik-Le Roux D., Renard J., V rine J., Renault V., Tubacher E., LeMaout J., **Rouas-Freiss N.**, Deleuze JF., Desgrandchamps F., Carosella ED.

Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients.

Mol Oncol. 2017 Nov;11(11):1561-1578.

d'Almeida TC, Sadissou I, Milet J, Cottrell G, Mond  re A, Avokpaho E, Gineau L, Sabbagh A, Massougbojji A, Moutairou K, Donadi EA, Favier B, Carosella E, Moreau P*, **Rouas-Freiss N***, Courtin D*, Garcia A*.

Soluble human leukocyte antigen -G during pregnancy and infancy in Benin: Mother/child resemblance and association with the risk of malaria infection and low birth weight.

PLoS One. 2017 Feb 6;12(2):e0171117

Rizzo R, Fainardi E, **Rouas-Freiss N**, Morandi F.

The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016.

J Immunol Res. 2017;2017:2309574.

Dupin C., Lhuillier E., L tuv  S., Bunel V., Thabut G., Mal, Carosella E.D., Pretolani M., Danel C., **Rouas-Freiss N.**, Brugi re O.

Human bronchial epithelium differentially modulates T-cell alloreactivity in lung transplant recipients compared to normal subjects through TGF- , IL-10, and HLA-G.

Transplantation, 2017 Sep;101(9):2192-2199.

Morandi F., Rizzo R., Fainardi E., **Rouas-Freiss N.**, Pistoia V.

Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases.

J Immunol Res. 2016;2016:4326495.

Du W-J., Reppel L., Avercenc L., Schenowitz C., Huselstein C., Bensoussan D., Carosella E.D., Han Z-C., **Rouas-Freiss N.**

Mesenchymal stem cells derived from human bone marrow and adipose tissue maintain their immunosuppressive properties after chondrogenic differentiation: role of HLA-G.

Stem Cells Dev. 2016 Oct 1;25(19):1454-69.

Gineau L, Courtin D, Camara M, Ilboudo H, Jamonneau V, Dias FC, Tokplonou L, Milet J, Mendon  a PB, Castelli EC, Camara O, Camara M, Favier B, **Rouas-Freiss N**, Moreau P, Donadi EA, Bucheton B, Sabbagh A, Garcia A.

Human leukocyte antigen-G: a promising prognostic marker of disease progression to improve the control of human African trypanosomiasis.

Clin Infect Dis. 2016 Nov 1;63(9):1189-1197.

d'Almeida T.C., Sadissou I., Cottrell G., Tahar R., Moreau P., Favier B., Moutairou K., Donadi E.A., Massougbojji A., **Rouas-Freiss N.**, Courtin D., Garcia A.

Evolution of the levels of human leukocyte antigen G (HLA-G) in Beninese infant during the first year of life in a malaria endemic area: using latent class analysis.

Malar J. 2016 Feb 9;15(1):78.

Carosella ED., **Rouas-Freiss N.**, Tronik-Le Roux D., Moreau P. leMaout J.

HLA-G: an immune checkpoint molecule.

Adv. Immunol. 2015;127:33-144.

Brugière O., Thabut G., Krawice-Radanne I., Rizzo R., Dauriat G., Danel C., Suberbielle C., Mal H., Stern M., Schilte C., Pretolani M., Carosella E.D., **Rouas-Freiss N.**

Role of HLA-G as a predictive marker of low risk of chronic rejection in lung transplant recipients: A clinical prospective study.

Am J Transplant. 2015 Feb;15(2):461-71.

Peltzer J., Montespan F., Thepenier C., Boutin L., Uzan G., **Rouas-Freiss N.** and Lataillade J.J.

Heterogeneous functions of Perinatal Mesenchymal Stromal Cells require a pre-selection before their banking for clinical use.

Stem Cells Dev. 2015 Feb 1;24(3):329-44.

Morandi F., **Rouas-Freiss N.**, Pistoia V.

The emerging role of soluble HLA-G in the control of chemotaxis.

Cytokine Growth Factor Rev. 2014 Jun;25(3):327-35.

Morandi F., Fainardi E., Rizzo R., **Rouas-Freiss N.**

The role of HLA-class Ib molecules in immune-related diseases, tumors and infections.

J. Immunol Res. 2014;2014:231618.

Naji A., Menier C., Morandi F., Agaogué S., Maki G., Ferretti E., Bruel S., Pistoia V., Carosella E.D., **Rouas-Freiss N.**

Binding of HLA-G to ITIM-bearing Ig-like receptors suppresses B cell responses

J. Immunol., 2014 Feb 15;192(4):1536-46.

Rouas-Freiss N., Moreau P., LeMaout J., Carosella E.D.

The dual role of HLA-G in cancer.

J. Immunol. Res. 2014;2014:359748.

Loumagne L., Baudhuin J., Favier B., Montespan F., D. Carosella E.D., **Rouas-Freiss N.**

In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.

Int J Cancer. 2014 Nov 1;135(9):2107-17.

Montespan F., Deschaseaux F., Sensébé L., Carosella E.D., **Rouas-Freiss N.**

Osteodifferentiated-Mesenchymal Stem Cells from Bone Marrow and Adipose Tissue Express HLA-G and Display Immunomodulatory Properties in HLA-Mismatched Settings: Implications in Bone Repair Therapy

J. Immunol. Res. 2014;2014:230346.

Leibler C., Matignon M., Pilon C., Montespan F., Bigot J., Lang P., Carosella E.D., Cohen J., **Rouas-Freiss N.**, Grimbert P., and Menier C.

Kidney transplant recipients treated with Belatacept exhibit increased naive and transitional B cells.

Am. J. Transpl., 2014 May;14(5):1173-82.

Sadissou I., d'Almeida T., Cottrell G., Luty A., Krawice-Radanne I., Massougbdji A., Moreau P., Moutairou K., Garcia A., Favier B., **Rouas-Freiss N.** and Courtin D.

High plasma levels of HLA-G are associated with low birth weight and with an increased risk of malaria in infancy

Malar J. 2014 Aug 12;13(1):312.

Naji A., **Rouas-Freiss N.**, Durrbach A., Carosella E.D., Sensebe L., Deschaseaux F.

Combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy.

Stem Cells, 2013 Nov;31(11):2296-303.

Courtin D., Milet J., Sabbagh A., Massaro JD., Castelli EC., Jamonneau V., Bucheton B., Sese C., Favier B., **Rouas-Freiss N.**, Moreau P., Donadi EA., Garcia A.
HLA-G 3' UTR-2 haplotype is associated with Human African trypanosomiasis susceptibility.
Infect Genet Evol. 2013 Jul;17:1-7.

Sabbagh A., Courtin D., Milet J., Massaro JD., Castelli EC., Migot-Nabias F., Favier B., **Rouas-Freiss N.**, Moreau P., Garcia A., Donadi EA.
Association of HLA-G 3' untranslated region polymorphisms with antibody response against *Plasmodium falciparum* antigens: preliminary results.
Tissue Antigens. 2013 Jul;82(1):53-8.

Garcia A., Milet J., Courtin D., Sabbagh A., Massaro JD., Castelli EC., Migot-Nabias F., Favier B., **Rouas-Freiss N.**, Donadi EA., Moreau P.
Association of HLA-G 3'UTR polymorphisms with response to malaria infection: A first insight.
Infect Genet Evol. 2013 Jun;16:263-9.

Martelli-Palomino G., Pancotto J.A., Muniz Y.C., Mendes-Junior C.T., Castelli E.C., Massaro J., Krawice-Radanne I., Poras I., Rebmann V., Carosella E.D., **Rouas-Freiss N.**, Moreau P., Donadi E.A.
Polymorphic sites AT 3' untranslated region of the HLA-G gene are associated with differential HLA-G Soluble levels in Brazilian and French populations.
Plos One, 2013 Oct 25;8(10):e71742.

Deschaseaux F., Gaillard J., Langonné A., Chauveau C., Naji A., Bouacida A., Rosset P., Heymann D., De Pinieux G., **Rouas-Freiss N.**, Sensébé L.
Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue
FASEB, 2013 Aug;27(8):2977-87.

Naji A., Menier C., Maki G., Carosella E.D., **Rouas-Freiss N.**
Neoplastic B cell growth is impaired by HLA-G/ILT2 interaction.
Leukemia, 2012 Aug;26(8):1889-92.

Zilberman S., Schenowitz C., Agaogué S., Benoît F., Riteau B., Rouzier R., Carosella E.D., **Rouas-Freiss N.**, Menier C.
HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment
Eur. J. Immunol., 2012 Jun;42(6):1599-608.

Agaogué S., Carosella E.D., **Rouas-Freiss N.**
Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinetic balance in favor of Th2 vs Th1/Th17
Blood, 2011 Jun 30;117(26):7021-31.

Lesport E., Baudhuin J., Sousa S., Lemaoult J., Zamborlini A., **Rouas-Freiss N.**, Carosella E.D., Favier B.
Inhibition of human Vγ9Vδ2 T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
Cell Mol Life Sci. 2011 68(20):3385-99.

Carosella E.D., Gregori S., **Rouas-Freiss N.**, Lemaoult J., Menier C., Favier B.
The role of HLA-G in immunity and hematopoiesis.
Cell Mol Life Sci. 2011 Feb;68(3):353-68.

Souto F.J., Crispim J.C., Ferreira S.C., da Silva A.S., Bassi C.L., Soares C.P., Zucoloto S., **Rouas-Freiss N.**, Moreau P., Martinelli A.L., Donadi E.A.

Liver HLA-G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection.

J Viral Hepat. 2011 Feb;18(2):102-5.

Bourguignon M., Yaghi L., Flajollet S., Radanne-Krawice I., **Rouas-Freiss N.**, Lugin D., Richalet J.P., Carosella E.D., Moreau P.

Increased soluble HLA-G levels in peripheral blood from climbers on Mount Everest.

Hum Immunol. 2010 Nov;71(11):1105-8.

Menier C., **Rouas-Freiss N.**, Favier B., LeMaout J., Moreau P., Carosella E.D.

Recent advances on the non classical major histocompatibility complex class I HLA-G molecule.

Tissue Antigens, 2010, 75:201-6.

Menier C., Prevot S., Carosella E.D., **Rouas-Freiss N.**

HLA-G is expressed in advanced-stage ovarian carcinoma of high grade histology.

Hum. Immunol., 2009, 70:1006-1009.

LeBouder F., Mandouri Y., Menier C., Keffous M., Lejal N., Krawice-Radanne I., Carosella E.D., **Rouas-Freiss N.** and Riteau B.

The immunosuppressive HLA-G molecule is up-regulated in alveolar epithelial cells after Influenza A virus infection.

Hum. Immunol., 2009, 70:1016-1019.

Bahri R., Naji A., Menier C., Charpentier B., Carosella E.D., **Rouas-Freiss N.**, Durrbach A. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance.

J. Immunol., 2009, 183:7054-7062.

Selmani Z., Naji A., Gaiffe E., Obert L., Tiberghien P., **Rouas-Freiss N.**, Carosella E.D., Deschaseaux F.

HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells.

Transplantation, 2009, 87:62-6.

Brugière O., Thabut G., Pretolani M., Krawice-Radanne I., Dill C., Herbreteau A., Poras I., Moreau P., Colombat M., Danel C., Dehoux M., Carosella E.D., **Rouas-Freiss N.**

Immunohistochemical study of HLA-G expression in lung transplant recipients.

Am. J. Transpl., 2009, 9:1427-1438.

Carosella E.D., Favier B., **Rouas-Freiss N.**, Moreau P., LeMaout J.

Beyond the increasing complexity of the immunomodulatory HLA-G molecule.

Blood, 2008, 111:4862-4870.

Maki G., Hayes G.M., Naji A., Tyler T., Carosella E.D., **Rouas-Freiss N.**, Gregory S.A.

NK Resistance of Tumor cells from Multiple Myeloma and Chronic Lymphocytic Leukemia patients: Implication of HLA-G.

Leukemia, 2008, 22:998-1006.

Sheshgiri R., **Rouas-Freiss N.**, Rao V., Butany J., Ramzy D., Krawice-Radanne I., Carosella E.D., Delgado D.

Endomyocardial Human Leukocyte Antigen-G Expression is a Reliable Marker of Allograft Tolerance in Heart Transplant Recipients.

J. Heart Lung Transpl., 2008, 27:522-7.

Carosella E.D., Moreau P., LeMaout J., **Rouas-Freiss N.**

HLA G: from biology to clinical benefits.

Trends in Immunology 2008, 29:125-132.

Menier C., Guillard C., Cassinat B., Carosella E.D., **Rouas-Freiss N.**
HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in Polycythemia Vera.
Leukemia 2008, 22:578-584.

Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., **Rouas-Freiss N.**, Carosella E.D., Deschaseaux F.
HLA-G5 secretion by Human Mesenchymal Stem Cells Is Required to Suppress T-lymphocyte and NK Function and to Induce CD4⁺CD25^{high}FOXP3⁺ Regulatory T Cells.
Stem Cells 2008, 26:212-22.

Naji A., Le Rond S., Durrbach A., Krawice-Radanne I., Creput C., Daouya M., Caumartin J., LeMaoult J., Carosella E.D., and **Rouas-Freiss N.**
CD3⁺CD4^{low} and CD3⁺CD8^{low} are induced by HLA-G: novel human peripheral blood suppressor T cell subsets involved in transplant acceptance.
Blood 2007, 110:3936-3948.

Rouas-Freiss N., Moreau P., Menier C., LeMaoult J., Carosella E.D.
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.
Semin. Cancer Biol., 2007, 17:413-421.

Sebti Y., Le Maux A., Gros F., De Guibert S., Pangault C., **Rouas-Freiss N.**, Bernard M., Amiot L.
Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders.
Br J Haematol. 2007, 138:202-12.

Monneret G., Voirin N., Lepape A., Krawice-Radanne I., **Rouas-Freiss N.**, Carosella E.D.
Soluble human leukocyte antigen-G5 in septic shock: marked and persistence elevation as predictor of survival.
Crit Care Med. 2007, 35:1942-1947.

Rouas-Freiss N., Naji A., Durrbach A., Carosella E.D.
Tolerogenic functions of HLA-G: from pregnancy to organ and cell transplantation.
Transplantation, 2007,84:S21-S25.

Fanchin R., Gallot V., **Rouas-Freiss N.**, Frydman R., Carosella E.D.
Implication of HLA-G in human embryo implantation.
Hum. Immunol., 2007, 68:259-263.

Favier B., LeMaoult J., **Rouas-Freiss N.**, Moreau P., Menier C., Carosella E.D.
Research on HLA-G: an update.
Tissue Antigens, 2007, 69:207-211.

Megret F., Prehaud C., Lafage M., Moreau P., **Rouas-Freiss N.**, Carosella E.D., Lafon M.
Modulation of HLA-G and HLA-E expression in human neuronal precursors after rabies virus or herpes virus simplex type-1 infections.
Hum. Immunol., 2007, 68:294-302.

Rebmann V., LeMaoult J., **Rouas-Freiss N.**, Carosella E.D, Grosse-Wilde H.
Quantification and identification of soluble HLA-G isoforms.
Tissue Antigens, 2007, 69:143-149.

Naji A., Durrbach A., Carosella E.D., **Rouas-Freiss N.**

Soluble HLA-G and HLA-G1-expressing antigen-presenting cells inhibit alloproliferation through ILT-2/ILT-4/FasL-mediated pathways.
Hum. Immunol., 2007, 68:233-239.

Beaudreuil S., Samuel D., **Rouas-Freiss N.**, Durrbach A.
New aspects of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?
Transpl. Immunol., 2007, 17:98-107.

Le Rond S., Azéma C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., **Rouas-Freiss N.**
Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells.
J. Immunol., 2006, 176:3266-3276.

Barhi R., Hirsch F., Josse A., **Rouas-Freiss N.**, Vasquez A., Carosella E.D., Charpentier B., Durrbach A.
Soluble HLA-G inhibits Cell Cycle Progression in Human Alloreactive T Lymphocytes.
J. Immunol., 2006, 176:1331-1339.

Zidi I., Guillard C., Marcou C., Krawice-Radanne I., Sangrouber D., **Rouas-Freiss N.**, Carosella ED, Moreau P.
Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.
Cell. Mol. Life Sci., 2006, 63:2669-2681.

Lafon M., Prehaud C., Megret F., Lafage M., Mouillot G., Roa M., Moreau P., **Rouas-Freiss N.**, Carosella E.D.
Modulation of HLA-G expression in human neural cells after neurotropic viral infections
J. Virol. 2005, 74:15226-15237.

Rouas-Freiss N., Moreau P., Ferrone S., Carosella E.D.
HLA-G proteins in cancer: an escape mechanism for tumor cells.
Cancer Res., 2005, 65:10139-10144.

LeMaoult J., **Rouas-Freiss N.**, Carosella ED.
HLA-G5 expression by trophoblast cells: the facts
Mol Hum Reprod. 2005, 11:719-22.

Le Rond S., Gonzalez A., Lopez Goncalvez A.S, Carosella E.D., **Rouas-Freiss N.**
IDO and HLA-G are two independent inhibitory signals of T cell alloproliferative response
Immunology, 2005, 116: 297-307.

Rebmann V., LeMaoult J., **Rouas-Freiss N.**, Carosella E.D, Grosse-Wilde H.
Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004
Hum. Immunol., 2005, 66:853-63.

LeMaoult J., **Rouas-Freiss N.**, Carosella E.D.
Immuno-tolerogenic functions of HLA-G: Relevance in transplantation and oncology
Autoimmun. Rev. 2005, 4:503-509.

Rouas-Freiss N., Bruel S., Menier C., Marcou C., Moreau P., Carosella E.D.
Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis
Int. J. Cancer, 2005, 117: 114-22.

Le Discorde M., Le Danff C., Moreau P., **Rouas-Freiss N.**, Carosella E.D.

HLA-G*0105N null allele encodes functional HLA-G isoforms.
Biol. Reprod., 2005, 73:280-288.

Nguyen S., Dhedin N., Vernant J-P, Kuentz M., Al Jijakli A., **Rouas-Freiss N.**, Carosella E.D., Boudifa A., Debre P., Vieillard V.
NK cell reconstitution after haploidentical hematopoietic stem cell transplants: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect.
Blood 2005, 105:4135-4142.

Mouillot G., Marcou C., Rousseau Ph., **Rouas-Freiss N.**, Carosella E.D., Moreau Ph.
HLA-G gene Activation in Tumor Cells Involves Cis-Acting Epigenetic Changes
Int. J. Cancer 2005, 113:928-936.

Menier C., Rabreau M., Challier J.C., Le Discorde M., Carosella E.D., **Rouas-Freiss N.**
Erythroblasts Secrete the Non Classical HLA-G Molecule from Primitive to Definitive Hematopoiesis.
Blood 2004, 104:3153-3160.

Le Rond S., LeMaoult J., Créput C., Menier C., Deschamps M., Le Fric G., Amiot L., Durrbach A., Dausset J., Carosella E.D., **Rouas-Freiss N.**
Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions : In vivo implications in transplanted patients.
Eur. J. Immunol. 2004, 34 :649-660.

Carosella E.D., Moreau P., Le Maoult J., Le Discorde M., Dausset J., **Rouas-Freiss N.**
HLA-G molecules: From maternal-fetal tolerance to tissue acceptance.
Adv. Immunol., 2003, 81:199-252.

Créput C., Le Fric G., Bahri R., Amiot L., Charpentier B., Carosella E.D., **Rouas-Freiss N.**, Durrbach A.
The detection of HLA-G in both serum and graft biopsy is associated with fewer acute rejections following combined liver-kidney transplantation : possible implications for the monitoring of patients
Hum. Immunol. 2003, 64:1033-1038.

Riteau B., Faure F., Menier C., Viel S., Carosella E.D., Amigorena S., **Rouas-Freiss N.**
Exosomes bearing HLA-G are released by melanoma cells.
Hum. Immunol. 2003, 64:1064-1072.

Créput C., Durrbach A., Menier C., Guettier C., Samuel D., Dausset J., Charpentier B., Carosella E.D., **Rouas-Freiss N.**
HLA-G expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation.
J. Hepatol, 2003, 39:587-594.

Rouas-Freiss N., Moreau P., Menier C., Carosella, E.D.
HLA-G in cancer: a way to turn off the immune system.
Semin. Cancer Biol., 2003, 13: 325-336.

Menier C., Saez B., Horejsi V., Martinozzi S., Krawice-Radanne I., Bruel S., Le Danff C., Reboul M., Hilgert I., Rabreau M., Larrad M.L., Pla M., Carosella E.D. and **Rouas-Freiss N.**
Characterization of Monoclonal Antibodies Recognizing HLA-G or HLA-E: New Tools to Analyze the Expression of Non Classical HLA Class I Molecules.
Hum. Immunol., 2003, 64: 315-326.

LeMaoult J., Le Discorde M., **Rouas-Freiss N.**, Moreau P., Menier C., McCluskey J., Carosella E.D.
Biology and functions of human leucocyte antigen-G in health and sickness.
Tissue Antigens 2003, 62:273-84.

Rouas-Freiss N., Le Maoult J., Moreau P., Dausset J., Carosella E.D.

HLA-G in transplantation : a relevant molecule for inhibition of graft rejection ?

Am. J. Transplant. 2003, 3: 11-16.

Menier C., Riteau B., Carosella E.D., **Rouas-Freiss N.**

MICA-triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.

Int. J. Cancer 2002, 100 :63-70.

Moreau P., Rousseau P., **Rouas-Freiss N.**, Le Discorde M., Dausset J., Carosella E.D.

HLA-G protein processing and transport to the cell surface.

Cell Mol. Life Sci. 2002, 59 : 1460-1466.

Moreau P., Dausset J., Carosella E.D., **Rouas-Freiss N.**

Viewpoint on the functionality of the human leucocyte antigen-G null allele at the fetal-maternal interface.

Biol. Reprod. 2002, 67 : 1375-1378.

Lozano M.J., González R., Kindelán J.M., **Rouas-Freiss N.**, Caballos R., Dausset J., Carosella E.D., Peña J.

Monocytes and T Lymphocytes in HIV-1 Positive Patients Express the Tolerogenic Molecule HLA-G.

AIDS. 2002, 16 :347-351.

Lila N., **Rouas-Freiss N.**, Dausset J., Carpentier A., Carosella E.D.

Soluble HLA-G protein secreted by allo-specific CD4⁺ T cells suppresses the allo-proliferative response : a CD4⁺ T cell regulatory mechanism.

Proc. Natl. Acad. Sci. USA 2001, 98 :12150-12155.

Riteau B., Menier C., Khalil-Daher I., Martinozzi S., Pla M., Dausset J., Carosella E.D., **Rouas-Freiss N.**

HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.

Int. Immunol. 2001, 13: 193-201.

Riteau B., **Rouas-Freiss N.**, Menier C., Paul P., Dausset J., Carosella E.D.

HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytotoxicity.

J. Immunol. 2001, 166 : 5018-5026.

Carosella E.D., Moreau P., Aractingi A., **Rouas-Freiss N.**

HLA-G: a shield against inflammatory aggression.

Trends in Immunol. 2001, 22 : 553-555.

Marchal R., **Rouas-Freiss N.**, Connan F., Choppin J., Dausset J., Carosella E.D., Kirszenbaum M., Guillet J.G.

A Soluble HLA-G Protein that Inhibits Natural Killer Cell-Mediated Cytotoxicity.

Transpl. Proceed. 2001, 33 : 2355-2359.

Riteau B., Moreau P., Menier C., Khalil-Daher I., Khosrotehrani K., Bras-Gonçalves R., Paul P., Dausset J., **Rouas-Freiss N.**, Carosella E.D.

Characterization of HLA-G1, G2, G3 and G4 Isoforms Transfected in a Human Melanoma Cell Line.

Transpl. Proceed. 2001, 33 : 2360-2364.

Torres M. I., Moreau P., **Rouas-Freiss N.**, Dausset J., Carosella E.D.

HLA-G Today.

Immunología 2001 ; 20 : 18-29.

Carosella E.D, Paul P., Moreau P., **Rouas-Freiss N.**

HLA-G and HLA-E: Fundamental and pathophysiological aspects.
Immunol. Today 2000, 21: 532-534.

Menier C., Riteau B., Dausset J., Carosella E.D., **Rouas-Freiss N.**

HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival.
Hum. Immunol. 2000, 61: 1118-1125.

Rabreau M., **Rouas-Freiss N.**, Landi M., Le Danff C., Carosella E.D.

HLA-G expression in trophoblast cells is independent of embryonic development.
Hum. Immunol. 2000, 61: 1108-1112.

Paul P., **Rouas-Freiss N.**, Moreau P., Adrian Cabestre F., Menier C., Khalil-Daher I., Pangault C., Onno M., Fauchet R., Martinez-Laso J., Morales P., Arnaiz-Villena A., Giacomini P., Natali P-G., Frumento G., Ferrara G-B., McMaster M., Fisher S., Schust D., Ferrone S., Dausset J., Geraghty D., Carosella E.D.

HLA-G, -E, -F preworkshop : tools and protocols for analysis of non classical class I genes transcription and protein expression.

Hum. Immunol. 2000, 61: 1177-1195.

Rouas-Freiss N., Paul P., Dausset J., Carosella E.D.

HLA-G Promotes Immune Tolerance.

J. Biol. Regul. Homeost. Agents 2000, 14 :93-98.

Khalil-Daher I., **Rouas-Freiss N.**, Carosella E.D., Dausset J.

HLA-G : Immunotolerant MHC Molecule in Transplantation.

World J. Surg. 2000, 24 : 819-822.

Carosella E.D., Dausset J., **Rouas-Freiss N.**

Transplacental Transmission of Natural-Killer-Cell Lymphoma.

N. Engl. J. Med. 1999, 25 : 1937.

Le Gal F.A., Riteau B., Sedlik C., Khalil-Daher I., Menier C., Dausset J., Guillet J.G., Carosella E.D., **Rouas-Freiss N.**

HLA-G Mediated Inhibition of Antigen Specific Cytotoxic T Lymphocytes.

Int. Immunol. 1999, 11 : 1351-1356.

Carosella E.D., **Rouas-Freiss N.**, Paul P., Dausset J.

HLA-G : A Tolerance Molecule from the Major Histocompatibility Complex.

Immunol. Today 1999, 20 : 60-62.

Rouas-Freiss N., Khalil-Daher I., Riteau B., Menier C., Paul P., Dausset J., Carosella E.D.

The Immunotolerance role of HLA-G.

Semin. Cancer Biol. 1999, 9 : 3-12.

Khalil-Daher I., Riteau B., Menier C., Sedlik C., Paul P., Dausset J., Carosella E.D., **Rouas-Freiss N.**

Role of HLA-G Versus HLA-E on NK Function : HLA-G is able to inhibit NK Cytolysis by Itself.

J. Reprod. Immunol. 1999, 43 : 175-182.

Carosella E.D., Dausset J., **Rouas-Freiss N.**

Immunotolerant Functions of HLA-G Molecule.

Cell Mol. Life Sci. 1999, 55 : 327-333.

Rouas-Freiss N., Khalil-Daher I., Marchal R., Menier C., Dausset J., Carosella E.D.

Role of HLA-G in Maternal-Fetal Immune Tolerance.

Transplant. Proceed. 1999, 31 : 724-725.

Carosella E.D., Khalil-Daher I., Dausset J., **Rouas-Freiss N.**
HLA-G Mediates Protection From Natural Killer Cytolysis : Implications in Immune Tolerance.
Transplant. Proceed. 1999, 31 : 1192-1193.

Adrian-Cabestre F., Moreau P., Riteau B., Ibrahim E.C., Le Danff C., Dausset J., **Rouas-Freiss N.**, Carosella E.D., Paul P.
HLA-G Expression in Human Melanoma Cells : Protection from NK Cytolysis.
J. Reprod. Immunol. 1999, 43 : 183-193.

Riteau B., Menier C., Khalil-Daher I., Sedlik C., Dausset J., **Rouas-Freiss N.**, Carosella E.D.
HLA-G Inhibits the Allogenic Proliferative Response.
J. Reprod. Immunol. 1999, 43 : 203-211.

Adrian-Cabestre F., Lefebvre S., Moreau P., **Rouas-Freiss N.**, Dausset J., Carosella E.D., Paul P.
HLA-G Expression : Immune Privilege for Tumour Cells ?
Semin. Cancer Biol. 1999, 9 : 27-36.

Paul P., **Rouas-Freiss N.**, Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G., Carosella E.D.
HLA-G Expression in Melanoma : a way for tumor cells to escape from Immunosurveillance.
Proc. Natl. Acad. Sci. USA 1998, 95(8) : 4510-4515.

Moreau P., Paul P., **Rouas-Freiss N.**, Kirszenbaum M., Dausset J., Carosella E.D.
Molecular and Immunologic Aspects of the Nonclassical HLA Class I antigen HLA-G. Evidence for an Important Role in the Maternal Tolerance of the Fetal Allograft.
Am. J. Reprod. Immunol. 1998, 40 : 136-144.

Rouas-Freiss N., Marchal R., Menier C., Dausset J., Carosella E.D.
Direct Evidence to Support the Role of HLA-G in Protecting the Fetus from Maternal Uterine Natural Killer Cytolysis.
Proc. Natl. Acad. Sci. USA. 1997, 94 : 11520-11525.

Rouas-Freiss N., Marchal R., Kirszenbaum M., Dausset J., Carosella E.D.
The $\alpha 1$ Domain of HLA-G1 and HLA-G2 Inhibits Cytotoxicity Induced by Natural Killer Cells : Is HLA-G the Public Ligand for Natural Killer Cell Inhibitory Receptors ?
Proc. Natl. Acad. Sci. USA. 1997, 94 : 5249-5254.

Housseau F., **Rouas-Freiss N.**, Roy M., Bidart J. M., Guillet J. G. and Bellet D.
Antigen presenting function of a gonadal epithelial cell line.
Cell. Immunol. 1997, 177:93-101.

Carcelain G., **Rouas-Freiss N.**, Zorn E., Chung-Scott V., Vieil S., Faure F., Bosq J., Hercend T.
In situ T cell responses in primary regressive melanoma and subsequent metastases: A comparative analysis.
Int. J. Cancer 1997, 72:241-247.

Housseau F., **Rouas-Freiss N.**, Benifla J. L., Marcillac I., Roy M., Troalen F., Fernandez H., Prapotnich D., Valencien G., Bougaran J., Cottu P., Culline S., Droz J. P., Bidart J. M. and Bellet D.
Reactivity of peripheral blood lymphocytes to the human chorionic gonadotropin β subunit in patients with productive tumors.
Int. J. Cancer 1995, 63:633-638.

Rouas N., Christophe S., Housseau F., Bellet D., Guillet J. G., and Bidart J. M.
Influence of protein-quaternary structure on antigen processing.

J. Immunol. 1993, 150:782-792.

Rouas-Freiss N., Housseau F., Bidart J. M., Bonnerot C., Amigorena S., Guillet J. G., and Bellet D.
Deficient antigen processing of a protein-quaternary structure can be overcome by receptor-mediated uptake.
Eur. J. Immunol. 1993, 23:3335-3344.

Rouas N., Christophe S., Bellet D., Troalen F., Guillet J. G., and Bidart J. M.
Immune recognition of a molecule naturally presented as a monomeric or an oligomeric structure: the model of the human chorionic gonadotropin α subunit.
Mol. Immunol. 1992, 29:883-893.

Bidart J.M., Troalen F., Ghillani P., **Rouas N.**, Razafindratsita A., Bohuon A., Bellet D.
Peptide Immunogen Mimicry of a Protein-Specific Structural Epitope on Human Choriogonadotropin
Science 1990, 248:736-739.

2. ORIGINAL ARTICLES IN NATIONAL PEER REVIEWED JOURNALS

Boulanger H., **Rouas-Freiss N.**, Cheid A., Biansomba N., Ahriz Saksi S., Drouin D., Guimiot F.
Interactions immunologiques cellulaires foeto-maternelles et prééclampsie précoce
Profession Sage-Femme n° 278 – Février 2022

Carosella E.D. Rouas-Freiss N.
Comment la mère tolère son fœtus.
Pour la Science. Dec. 2011. N°410

LeBouder F., Mandouri Y., Menier C., Lejal N., **Rouas-Freiss N.**, Riteau B.
Un point sur la pathogénicité des virus Influenza: rôle des protéases et de la molécule immunosuppressive HLA-G
Virologie 2010, 14, Numéro 3

Rouas-Freiss N., Carosella E.D.
Expression de HLA-G au cours de la gestation: rôle immunologique dans la tolérance foeto-maternelle et le développement normal et pathologique de la grossesse
Reprod. Hum., 2007, 3 :176-180

LeMaoult J., **Rouas-Freiss N.**, Teyssier-Le Discorde M., Moreau Ph., Carosella E.D.
HLA-G en transplantation d'organes.
Pathol. Biol. 2004, 54 :97-103.

Créput C., Durrbach A., Charpentier B., Carosella E.D., **Rouas-Freiss N.**
HLA-G : une molécule immunorégulatrice impliquée dans l'acceptation d'organe
Néphrologie, 2003, 24 :451-456.

Le Discorde M., Moreau Ph., **Rouas-Freiss N.**, Carosella E.D.
HLA-G : Immunotolérance en Physiologie Normale et Pathologique.
Pathol. Biol. 2002, 52 : 45-51.

Paul P., **Rouas-Freiss N.**, Carosella E.D.
HLA-G une Molécule de Tolérance Impliquée dans l'Echappement des Tumeurs à la Surveillance Immunitaire.
Pathol. Biol. 1999 ; 47 : 766-770.

Rouas-Freiss N., Carosella E.D.
HLA-G : Une Molécule de Tolérance.
Hématol. 1998 ; 4 : 110-112.

Carosella E.D., **Rouas-Freiss N.**, Paul P., Dausset J.
Comment le Foetus échappe aux Défenses de sa Mère.
La Recherche 1998 ; 307 : 36-38.

Rouas-Freiss N., Dausset J., Carosella E.D.
Tolérance foetomaternelle: rôle des molécules HLA-G présentes à la surface des cellules trophoblastiques.
Reprod. Hum. 1998, 5: 421-424.

Rouas-Freiss N., Kirszenbaum M., Dausset J., Carosella E.D.
Tolérance foeto-maternelle : Rôle de la molécule HLA-G dans la protection du fœtus contre l'activité Natural Killer maternelle"
C. R. Acad. Sci. 1997 ; 320 : 385-392.

Hercend T., Zorn E., Carcelain G. and **Rouas-Freiss N.**
Analyse comparative de la réponse immunitaire dans un cas de mélanome primitif régressif suivi d'une métastase gastrique.
Bul. Acad. Natle. Med. 1995, 179 n°3:677-692.

Rouas N., Bidart J. M., Bellet D.
Interactions cellulaires au cours de la réponse immunitaire.
Immunoanal. Biol. Spéc. 1993, 8:9-15.

3. CHAPTERS OF SCIENTIFIC BOOKS

Menier C, **Rouas-Freiss N.**, Carosella ED.
The HLA-G non classical MHC class I molecule is expressed in cancer with poor prognosis. Implications in tumour escape from immune system and clinical applications. Atlas Genet Cytogenet Oncol Haematol. July 2008 .

Moreau P., **Rouas-Freiss N.**, Pangault C., Fauchet R., Arnaiz-Villena A., Ferrara G.B., Carosella E.D.
Protocols and tools for RT-PCR analysis of non classical HLA-class I gene transcription
HLA 2002 Immunobiology of the Human MHC. 13th IHWG

Rouas-Freiss N., Moreau P., Pangault C., Fauchet R., Arnaiz-Villena A., Ferrara G.B., Carosella E.D.
Recent results on characterization of new anti-HLA-G and anti-HLA-E antibodies
HLA 2002 Immunobiology of the Human MHC. 13th IHWG

Menier C., Riteau B., Bruel S., Carosella E.D., **Rouas-Freiss N.**
Antagonistic Role of HLA-G1 and MICA Ligands in Tumor Immunosurveillance Mediated by NK Cells.
HLA 2002 Immunobiology of the Human MHC. 13th IHWG

Lila N., **Rouas-Freiss N.**, Dausset J., Carpentier A., Carosella E.D.
Soluble HLA-G Protein Secreted by Allo-Specific CD4⁺Tcells Suppresses the Allo-Proliferative Response.
HLA 2002 Immunobiology of the Human MHC. 13th IHWG

Rouas-Freiss N., Menier C., Carosella E.D
MHC Expression in the Human Placenta and Role of HLA-G.
Falk Workshop "Bile Acids and Pregnancy". Edited by U. Leuschner, klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Germany (2002) : chapitre 4, page 18.

Carosella E.D., **Rouas-Freiss N.**
Rôle de la molécule HLA-G dans la tolérance foeto-maternelle et l'implantation embryonnaire
Dans Implantation et placentation paru en 2000 aux éditions MASSON

Bellet D., **Rouas N.**, Marcillac I., Housseau F., Cottu P., Troalen F., Bidart J. M.

Free hCG β and nongonadal neoplasms.

In Glycoprotein Hormones: Structure, Function and Clinical Implications. Lustbader J. W., Puett J. D., and Ruddon R. 1993, Vol.20 p.264-280.

4. PRODUCTS INTENDED FOR THE GENERAL PUBLIC

Emission de radio: France Culture/La méthode scientifique le 7/01/2019
« Greffe: l'impossible puzzle biologique »

Fête de La Science: Welcoming the general public and presenting the department's research

5. NATIONAL AND INTERNATIONAL INVITED CONFERENCES

- Tolérance foeto-maternelle: Focus sur le rôle de la molécule HLA-G. *11ème rencontre du Groupe de la Francophonie Placentaire*, Paris 2026.
- An Immune Checkpoint with Broad Immune-Inhibitory Functions through Interaction with ILT2/ILT4 Receptors. *10th International Conference on HLA-G*, Ferrara, Italy 2025.
- HLA-G: a non-classical class I molecule with immune checkpoint functions. *Webinaire scientifique de la SFHI*, 2025.
- Greffons de peau issus de culture et rejet de greffe : un domaine pionnier en médecine régénératrice. *Conférence FOCUS CEA*, Paris, France 2024.
- HLA-G in solid organ transplantation. *15th International Congress on lung transplantation*, Paris, France 2022.
- HLA-G: HLA-G/ILT2/ILT4 immune checkpoint: Function and clinical applications. *9th International Conference on HLA-G*, Paris, France 2022.
- HLA-G : Un Checkpoint Immunitaire en Transplantation et Oncologie. *Séminaire Clinique de l'Hôpital Foch*, Suresnes, France, 2022
- HLA-G: Where are we? *16th Annual Meeting of the European Society for Reproductive Immunology*, Paris, France, 2022.
- HLA-G: an immune checkpoint molecule in oncology and transplantation. *Séminaire IRSL Hôpital Saint-Louis*, Paris France, 2020.
- HLA-G: a major immune checkpoint. *8th International Conference on HLA-G*, Paris, France 2019.
- Molécule HLA-G: de la grossesse à la greffe d'organes. *Séminaire scientifique du centre CEA de Fontenay-aux-Roses*, France, 2017.
- Mesenchymal stem cells derived from human bone marrow and adipose tissue maintain their immunosuppressive properties after chondrogenic differentiation: role of HLA-G. *6th International Symposium Europe China « Mesenchymal Stem Cells and Regenerative Medicine*, Nancy, France 2016.
- HLA-G from basic research to clinical applications in oncology. *Laboratoire Pierre Fabre*, Genève, Suisse 2015.
- HLA-G in normal and neoplastic B cells. *7th International Conference on HLA-G*, Paris, France 2015.
- Table ronde scientifique franco-chinoise en médecine régénérative, *Université de Wuhan*, Wuhan, Chine 2014.
- HLA-G, a tolerogenic molecule. *Faculté de Pharmacie – IRD*, Paris, France 2014.
- Role of HLA-G in immunosuppressive properties of mesenchymal stem cells. *Académie Nationale de Médecine*, Paris, France 2013.
- HLA-G in B cell responses. *6th International Conference on HLA-G*, Paris, France 2012.
- HLA-G: from maternalfetal tolerance to allograft acceptance. *Faculté de Pharmacie de Natal*, Brésil 2012.
- Identify low immunogenic MSC types to be used in HLA-mismatched settings. *7th European Program REBORNE*, Frankfurt, Germany 2012.

- HLA-G: Rôle en transplantation d'organes. *Unité INSERM U700, Hôpital Bichat*, Paris, France 2011.
- Measurement of soluble HLA-G in biologic fluids. *Projet ANR Tolimmunpal*. Faculté des Saint-Pères Paris, France 2011.
- Inhibition of B cell functions through HLA-G and ITIM-bearing Ig like receptors interaction: Implications in the control of chronic graft dysfunction. *17th NAT meeting*, Nantes, France 2011.
- HLA-G: Immune fonctions and implications in oncology and transplantation. *Gaslini Institute of Genova*, Genova, Italy 2010.
- Rôle de HLA-G en pathologies humaines. *IRD Faculté de Pharmacie Paris*, France 2010.
- Présentation des travaux de l'équipe " HLA-G: du Fondamental à la Clinique". *Journées des Directeurs CEA-DSV*, Saclay, France 2009.
- Role of HLA-G in allograft acceptance: expression by mesenchymal stem cells and modulation of B cell response. *5th International Conference on HLA-G*, Paris, France, 2009.
- HLA-G : Traitement des Pathologies Tumorales Lymphocytaires B. *Journée Valorisation CEA-Transgène*, Fontenay-aux-Roses, France, 2009.
- HLA-G : Applications Thérapeutiques en Transplantation et Cancérologie. *Journée Immunologie CEA-DSV*, Fontenay-aux-Roses, France, 2009.
- HLA-G: de la tolérance foeto-maternelle à l'acceptation des greffes. *Séminaire scientifique du centre CEA de Fontenay-aux-Roses*, France, 2008
- Role of HLA-G in Allograft Acceptance through Induction of Regulatory T Cells, *French-Israeli workshop on regulatory T cells*, Jérusalem, Israël, 2008.
- De la tolérance foeto-maternelle à l'acceptation du greffon. *Colloque de Recherche en Transplantation. Institut de France, Académie des Sciences*, Paris, 2008.
- De la tolérance foeto-maternelle à l'acceptation du greffon. *Journées Scientifiques Franco-Argentines*, Paris, France, 2008.
- Caractérisation des fonctions immunosuppressives de la molécule HLA-G: Implications en Transplantation et Cancérologie. *IUH, Hôpital Saint-Louis*, Paris, France, 2007.
- HLA-G and Immune Aspects of Mesenchymal Stem Cells. *Genostem 2007 Symposium on Mesenchymal Stem Cells, Gene and Stem Cell Therapy Approaches for Connective Tissue Disorders*, Montpellier, France, 2007.
- Fonctions de tolérance immunitaire de HLA-G : Applications en transplantation. *Institut de Recherche en Transplantation*, Nantes, France, 2007.
- Tolerogenic functions of HLA-G: from pregnancy to transplantation. *Department of Immunology, University of Córdoba*, Spain, 2007.
- Role of HLA-G in allograft acceptance through the induction of immunosuppressive/regulatory T cells. *4th International Conference on HLA-G*, Paris, France, 2006.
- Tolerogenic functions of HLA-G in Transplantation. *Institute for Immunology, Essen University*, Germany, 2006.
- Fonctions tolérogéniques de HLA-G: de la grossesse à la transplantation. *6th Beaune Seminar in Transplant Research*, Beaune, France, 2006.
- HLA-G en transplantation. *Service de Chirurgie Cardiaque, Hôpital Broussais*, Paris, France, 2006.
- Expression de HLA-G au cours de la gestation: Implications physiopathologiques. *Réunion du groupe français sur l'étude du placenta*, Antony, France, 2006.
- HLA-G expression in Melanoma. *VI Course on Advances in Dermatologic Surgery and Melanoma*, Pamplona, Spain, 2006.
- HLA-G et profil d'implantation embryonnaire. *Service de Gynécologie Obstétrique, Hôpital Antoine Bécère*, Clamart, France, 2005.
- Characterization of Monoclonal Antibodies Recognizing HLA-G. *Wet-workshop for quantification of soluble HLA-G*, Essen, Germany, 2004.
- Fonctions immunosuppressives de HLA-G : implications en pathologies. *Service d'Immunologie et Virologie*, Jouy-en-Josas, France, 2004.

- HLA-G : De la tolérance du fœtus à l'acceptation des tissus adultes. *Service de Gynécologie Obstétrique, Hôpital Antoine Bécclère, Clamart, France, 2004.*
- HLA-G in cancer: a way to turn off the immune system. *3rd International Conference on HLA-G, Paris, 2003.*
- Characterization of antibodies recognizing HLA-G and HLA-E. *Workshop session, 3rd International Conference on HLA-G, Paris, 2003.*
- The MICA-triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. *International Congress of Histocompatibility and Immunogenetics, Seattle, USA, 2002.*
- Workshop presentation on HLA-G and HLA-E antibodies. *International Histocompatibility Workshop, Victoria, Canada, 2002.*
- HLA-G, une molécule d'immuno-tolérance dans la greffe cardiaque, la greffe rénale et la double greffe simultanée rein/foie. *Service de Néphrologie et de Transplantation, Hôpital Henri Mondor, Créteil, France, 2002.*
- MHC expression in the human placenta and role for HLA-G. *Falk Workshop on Bile Acids and Pregnancy, Freiburg, Germany, 2002.*
- HLA-G in immunotolerance. *European Symposium on Platelet, granulocyte and red cell immunobiology, Belgirate, Italy, 2002.*
- Fonctions de tolérance immunitaire de HLA-G et implications en physiopathologie. *Service Hospitalier Frédéric Joliot, Orsay, France, 2002.*
- Implications de la molécule HLA-G au cours de processus tumoraux et de transplantation. *Hôpital Robert Debré, Paris, France, 2002.*
- Implication of HLA-G in maternal-fetal tolerance. *International Congress of Immunology, Stockholm, Sweden, 2001.*
- Workshop presentation on HLA-G and HLA-E. *2nd International Conference on HLA-G, Paris, France, 2000.*
- Expression and function of HLA-G molecules: Implication in immuno-surveillance. *2nd International Conference on HLA-G, Paris, France, 2000.*
- Immunological function of HLA-G. *Institut for Anthropology and Human Genetic, Munich, Germany, 2000.*
- HLA-G, une molécule de tolérance immunitaire : de la grossesse à la transplantation. *Conférences d'actualité, Faculté de Médecine des Saints-Pères, Paris, France, 2000.*
- Relations structure-fonction de la molécule HLA-G. *Hôpital Saint-Louis, Paris, France, 2000.*
- Role of HLA-G in maternal-fetal tolerance. *International symposium on microchimerism. Paris, France, 1999.*
- Caractérisation des fonctions immunologiques de la molécule HLA-G et implications en physiopathologie. *CEPH, Paris, France, 1999.*
- Immunological function of HLA-G. *1st International Conference on HLA-G, Paris, France, 1998.*
- Etude immunologique de la molécule HLA-G : implications dans la tolérance foeto-maternelle. *Journées d'Hématologie, Paris, France, 1997.*
- Réponse immune dirigée contre l'hCG β chez des patients atteints d'un cancer de la vessie. *Institut Gustave Roussy, Villejuif, France, 1994.*
- Réponse immune dirigée contre l'hormone chorionique gonadotrope humaine : implications en pathologies tumorales. *Institut Curie, Paris, France, 1993.*
- Réponse immune dirigée contre l'hormone chorionique gonadotrope humaine. *Hôpital Cochin, Paris, France, 1993.*
- Influence of the quaternary-structure of Human Choriogonadotropin in T cell recognition. *Meeting of the European Federation of Immunological Societies. Helsinki, Finland, 1991.*

6. PATENTS

- **Rouas-Freiss N., LeMaout J., Culine S., Dumont C.** Novel T cell populations as markers for predicting toxicity and effectiveness of immune checkpoint blockade-based therapies. 2025. Demande de brevet

européen n° EP25305033.0 déposé le 13 janvier 2025. Demande internationale PCT/EP2026/050518 du 12 janvier 2026.

- **Rouas-Freiss N.**, LeMaout J., Carosella ED., Brugiere O., Dreyfuss D., Guilet R. Methods for determining the likelihood of occurrence of bronchiolitis obliterans syndrome in a lung transplant recipient. 2023. Demande de brevet européen n° EP23305466 déposé le 31/03/2023. Demande Internationale publiée le 3 octobre 2024 sous le n° WO 2024/200804 A1.
- LeMaout J., **Rouas-Freiss N.**, Carosella ED., Brugiere O., Mouren D. Novel T cells and the uses thereof. 2020. Demande de brevet européen n° EP 0 305861.5. Demande internationale publiée le 3 février 2022 sous le n° WO 2022/023236 A1.
- Carosella ED., LeRoux D., Deslys JP., Verine J., Desgrandchamps F., **Rouas-Freiss N.**, Le Maout J. Ciblage du point de contrôle HLA-G pour l'immunothérapie. Demande internationale PCT/EP2018/070061 du 24 juillet 2018. Texte publié le 31 janvier 2019 sous le n°WO2019/020641A1.
- Deschaseaux F., Sensebe L., **Rouas-Freiss N.** Utilisation d'une isoforme d'HLA-G comme agent anti-résorption osseuse. Brevet français déposé le 23/11/2010 sous le n° FR10 59653. Demande Internationale PCT/IB201 1/055255 du 23 novembre 2011. Texte publié le 31 mai 2012 sous le n° WO2012/070003.
- Deschaseaux F., Sensebe L., **Rouas-Freiss N.**, Naji A., Carosella E.D. Utilisation d'une isoforme d'HLA-G comme marqueur de l'ostéogénèse. Brevet français n° 09 05624 déposé le 23 novembre 2009. Demande Internationale PCT/IB2010/055380 du 23 novembre 2010. Texte publié le 26 mai 2011 sous le n° WO2011/061726.
- **Rouas-Freiss N.**, Carosella E.D. Utilisation d'une forme soluble de HLA-G dans le traitement des proliférations anormales des lymphocytes B. Demande internationale PCT/FR2009/000965 déposée le 31.07.2009, publiée le 04.02.2010, sous le n° WO2010012912.
- Menier C., Carosella E.D., **Rouas-Freiss N.** Application des isoformes solubles HLA-G dans le traitement des désordres myéloprolifératifs associés à une tyrosinase kinase JAK2 anormale. Brevet français n° 07 01139 déposé le 16 février 2007.
- Aractingi S., Dausset J., Carosella E.D., Paul P., Khalil-Daher I., Moreau P., **Rouas-Freiss N.** Utilisation de compositions contenant des formes solubles d'HLA-G dans le traitement de pathologies inflammatoires de la peau, et de leur procédé d'obtention. Brevet Français n° 99 07736 déposé le 18 Juin 1999. Demande Internationale PCT/FR00/01670 du 16 Juin 2000. Texte publié le 28 décembre 2000, sous le n° WO 00/78337.
- Carosella E.D., Dausset J., Moreau P., Paul P., **Rouas-Freiss N.** Méthode de sélection de tumeurs exprimant HLA-G sensibles à un traitement anti-cancéreux et ses applications. Brevet Européen n° 99 904 919.0 déposé le 19 février 1999. Publié le 29 Novembre 2000 sous le n° 1 054 688. Demande Internationale PCT BLOcf263/38PCT, texte publié le 26 Août 1999, sous le n° WO 99 42128.
- Carosella E. D., Dausset J., Kirszenbaum M., P. Paul, **Rouas-Freiss N.** Cellules eucaryotes exprimant à leur surface au moins une isoforme de HLA-G et leurs applications. Brevet Européen n°0917538 du 20 février 1998, délivré le 20.01 2010.
- **Rouas-Freiss N.**, Bidart J. M., Bellet D., Troalen F. Trousse de diagnostic d'un cancer sécrétant l'hCG ou des fragments d'hCG et vaccin destiné à l'immunothérapie d'un tel cancer. n° 93.02820.